284 related articles for article (PubMed ID: 29906029)
1. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
Vargas-Aguilar VM; Arroyo-Alvarez K
Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
[TBL] [Abstract][Full Text] [Related]
2. Multigene prognostic tests in breast cancer: past, present, future.
Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
[TBL] [Abstract][Full Text] [Related]
3. Mammaprint™: a comprehensive review.
Brandão M; Pondé N; Piccart-Gebhart M
Future Oncol; 2019 Jan; 15(2):207-224. PubMed ID: 30156427
[TBL] [Abstract][Full Text] [Related]
4. Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
Bernhardt SM; Dasari P; Wrin J; Raymond W; Edwards S; Walsh D; Townsend AR; Price TJ; Ingman WV
Breast Cancer Res; 2020 Aug; 22(1):90. PubMed ID: 32811558
[TBL] [Abstract][Full Text] [Related]
5. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
[TBL] [Abstract][Full Text] [Related]
6. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
Markopoulos C; van de Velde C; Zarca D; Ozmen V; Masetti R
Eur J Surg Oncol; 2017 May; 43(5):909-920. PubMed ID: 27639633
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
[TBL] [Abstract][Full Text] [Related]
8. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
Kwon MJ
Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
[TBL] [Abstract][Full Text] [Related]
9. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.
Gyanchandani R; Lin Y; Lin HM; Cooper K; Normolle DP; Brufsky A; Fastuca M; Crosson W; Oesterreich S; Davidson NE; Bhargava R; Dabbs DJ; Lee AV
Clin Cancer Res; 2016 Nov; 22(21):5362-5369. PubMed ID: 27185370
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
Colomer R; Aranda-López I; Albanell J; García-Caballero T; Ciruelos E; López-García MÁ; Cortés J; Rojo F; Martín M; Palacios-Calvo J
Clin Transl Oncol; 2018 Jul; 20(7):815-826. PubMed ID: 29273958
[TBL] [Abstract][Full Text] [Related]
11. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
Dobbe E; Gurney K; Kiekow S; Lafferty JS; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(1):23-8. PubMed ID: 18159035
[TBL] [Abstract][Full Text] [Related]
12. Gene expression signatures in early breast cancer: Better together with clinicopathological features.
Oliveira LJC; Amorim LC; Megid TBC; de Resende CAA; Mano MS
Crit Rev Oncol Hematol; 2022 Jul; 175():103708. PubMed ID: 35580764
[TBL] [Abstract][Full Text] [Related]
13. Predicting risk of breast cancer recurrence using gene-expression profiling.
Ignatiadis M; Desmedt C
Pharmacogenomics; 2007 Jan; 8(1):101-11. PubMed ID: 17187513
[TBL] [Abstract][Full Text] [Related]
14. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
15. Gene-Expression-Based Predictors for Breast Cancer.
Gupta A; Mutebi M; Bardia A
Ann Surg Oncol; 2015 Oct; 22(11):3418-32. PubMed ID: 26215189
[TBL] [Abstract][Full Text] [Related]
16. Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.
Jahn SW; Bösl A; Tsybrovskyy O; Gruber-Rossipal C; Helfgott R; Fitzal F; Knauer M; Balic M; Jasarevic Z; Offner F; Moinfar F
Br J Cancer; 2020 Jun; 122(12):1744-1746. PubMed ID: 32336753
[TBL] [Abstract][Full Text] [Related]
17. Markers for the identification of late breast cancer recurrence.
Sestak I; Cuzick J
Breast Cancer Res; 2015 Jan; 17(1):10. PubMed ID: 25848913
[TBL] [Abstract][Full Text] [Related]
18. Gene expression signatures in older patients with breast cancer: A systematic review.
Lemij AA; Baltussen JC; de Glas NA; Kroep JR; Derks MGM; Liefers GJ; Portielje JEA
Crit Rev Oncol Hematol; 2023 Jan; 181():103884. PubMed ID: 36442749
[TBL] [Abstract][Full Text] [Related]
19. Molecular signatures in breast cancer.
Lal S; McCart Reed AE; de Luca XM; Simpson PT
Methods; 2017 Dec; 131():135-146. PubMed ID: 28669865
[TBL] [Abstract][Full Text] [Related]
20. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
